Radiotheranostics pairs molecular imaging with targeted radioactive drugs, allowing clinicians to confirm whether a tumor carries the therapeutic target before delivering radiation systemically.
Discover how Radnostix’s Lucerno Dynamics deal could reshape radiopharmaceutical monitoring, dosimetry and theranostics delivery.
Curasight A/S has dosed the first patient in a Phase 1 clinical trial of uTREAT for glioblastoma, launching the therapeutic half of its uPAR-targeting theranostic platform alongside its companion diagnostic, uTRACE, which is already in Phase 2 for prostate cancer. How curative ambitions shift when a theranostic platform enters human testing in glioblastoma Curasight’s advancement